SALT LAKE CITY, UTAH – June 4, 2018 – MultiFunctional Imaging LLC announced today that its mfiVerse™ software has received FDA 510(k) clearance for rest-stress myocardial perfusion PET imaging. This makes mfiVerse™ the first and only device cleared by the FDA that provides single-scan or fast back-to-back rest+stress cardiac PET images with approved radiotracers.

"mfiVerse™ is an exciting advance in cardiac imaging," stated Dan Kadrmas, President and Chief Science Officer of MFI. "Until now, there has not been an approach to rapidly acquire rest and stress cardiac PET images in a single scan. mfiVerse™ represents a breakthrough by enabling MPI PET exams under 30 minutes with all approved perfusion radiotracers, providing improved patient experience while doubling scanning capacity."

Myocardial perfusion imaging (also referred to as MPI) is a nuclear medicine procedure that illustrates the function of the heart muscle. It is widely used to evaluate patients with known or suspected heart disease and can identify ischemia, infarct, and heart wall motion abnormalities. In the United States, approximately 10 million people each year undergo a myocardial perfusion exam.

MultiFunctional Imaging LLC is a medical device company dedicated to the development of patented technologies for single-scan myocardial perfusion imaging, single-scan multi-tracer cancer imaging for quantification and assessment of tumor function, and tools for multi-tracer PET research and kinetic modeling. The mfiVerse™ clinical software has 510(k) clearance for rest-stress cardiac imaging, and MFI's mfEVolve™ research software is available for multi-tracer and kinetic modeling research. MultiFunctional Imaging LLC was created in 2014 as a spin-out from the University of Utah. For more information, please visit www.MultiFunctionalImaging.com.

Contact:
Dave Dolan, Chairman
Dave.Dolan@MFImage.com